AC220 for Children With Relapsed/Refractory ALL or AML
Public ClinicalTrials.gov record NCT01411267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
Study identification
- NCT ID
- NCT01411267
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 24 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 1 Month to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2011 (Actual)
- Primary completion
- Sep 12, 2013 (Actual)
- Completion
- Sep 12, 2013 (Actual)
- Last update posted
- Apr 4, 2022
2011 – 2013
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| Children's Hospital Central California | Madera | California | 93636 | — |
| UCSF School of Medicine | San Francisco | California | 94143-0106 | — |
| The Children's Hospital, University of Colorado | Aurora | Colorado | 80045 | — |
| Children's Healthcare of Atlanta, Emory University | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University | Baltimore | Maryland | 21231 | — |
| Dana Farber | Boston | Massachusetts | 02215 | — |
| Children's Mercy Hospitals and Clinics | Kansas City | Missouri | 64108 | — |
| Levine Children's Hospital at Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01411267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01411267 live on ClinicalTrials.gov.